Market cap rebound by top 20 biopharmaceutical companies in Q2 2023 - Pharmaceutical Technology
Biogen CEO Calls Share Slump an Overreaction to Alzheimer's Trial - WSJ
Biogen Market Cap 1995 | StatMuse Money
Biogen Inc. (NASDAQ:BIIB) Shares Sold by LSV Asset Management - MarketBeat
Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects | Seeking Alpha
In the wake of Biogen Inc.'s (NASDAQ:BIIB) latest US$1.4b market cap drop, institutional owners may be forced to take severe actions - Simply Wall St News
Biogen (BIIB) $18 Billion Plunge May Have Hurt These Hedge Funds - Bloomberg
Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors
Biogen 2019 Outlook (NASDAQ:BIIB) | Seeking Alpha
Biogen Inc. (BIIB Stock) Breaks Out, Will BIIB Reach $300?
Biogen shares soar on landmark Alzheimer's data, lift rivals | Reuters
Analysts expect over 2021 decreasing revenue Biogen | Valuespectrum.com
SEC Filing | Biogen
Bloomberg on X: "Experimental Alzheimer's drug helps add $40 billion to Biogen's stock value http://t.co/3cz3AQl9rw http://t.co/N3UdtSlZk9" / X
Market Data - BIOGEN (NASD)
Biogen's $11 bln Alzheimer's gain has cushion | Reuters
SEC Filing | Biogen
What Is The Market Cap Of Biogen | StatMuse Money
Biogen: Strong Prospects With A Low Valuation (NASDAQ:BIIB) | Seeking Alpha
Unveiling Biogen (BIIB)'s Value: Is It Really Priced Right? A Comprehensive Guide
Biogen Stock Forecast, price, news, analysis (BIIB) | Strike.Market
Biogen - Wikipedia
Is Biogen Stock a Buy Now? | The Motley Fool
Shock revelation sees Biogen erase its aducanumab losses | Evaluate
Biogen NPS & Customer Reviews | Comparably
